SCHEMBL10244409

SCHEMBL10244409

COC[C@@H](C)NC(=O)c1cc(-c2ccc(C)cn2)cc(-n2nnnc2C(C)C)c1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 9/20 0.60
P2RX2 Q9UBL9 9/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4323088 1.00 P2RX3 (0.60) P2RX3P2RX2
SCHEMBL4323150 0.90 P2RX3 (0.59) P2RX3P2RX2
SCHEMBL4336377 0.90 P2RX3 (0.60) P2RX3P2RX2
SCHEMBL10244099 0.88 P2RX3 (0.51) P2RX3P2RX2
SCHEMBL10243941 0.88 P2RX3 (0.51) P2RX3P2RX2
SCHEMBL16883508 0.88 P2RX3 (0.51) P2RX3P2RX2
SCHEMBL4329531 0.88 P2RX3 (0.58) P2RX3P2RX2
SCHEMBL4324297 0.88 P2RX3 (0.58) P2RX3P2RX2
SCHEMBL4316333 0.86 P2RX3 (0.56) P2RX3P2RX2
SCHEMBL4317185 0.85 P2RX3 (0.56) P2RX3P2RX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193368-B2 Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists ROCHE PALO ALTO LLC (US) 2012-06-05 US disclosed
US-8193368-B2 Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists ROCHE PALO ALTO LLC (US) 2012-06-05 US disclosed
US-20090326220-A1 Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists DILLON MICHAEL PATRICK 2009-12-31 US disclosed
US-20090326220-A1 Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists DILLON MICHAEL PATRICK 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326220-A1 Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists P2RX3, P2RX2, P2RX5 P2RX3 1/4885P2RX2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.